Healthcare Industry News: SUTENT
News Release - July 23, 2007
Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical OfficerCAMBRIDGE, Mass., July 23 (HSMN NewsFeed) -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for autoimmune disease and cancer, today announced that William Slichenmyer, M.D. has joined Merrimack as Senior Vice President and Chief Medical Officer.
"Merrimack is at the critical point of guiding MM-093 through phase 2 trials in autoimmune disease while preparing for our first oncology therapeutic, MM-121, to enter into the clinic early next year," said Dr. Slichenmyer. "I am excited to help lead the team in leveraging our Network Biology approach to build on our research and development capabilities and to move our robust and innovative pipeline of products into the clinic."
Dr. Slichenmyer joins a diverse and experienced management team comprised of Robert Mulroy, President and CEO, Lisa Evren, SVP and CFO, Fazal Khan, Ph.D., VP of Manufacturing, and Ulrik Nielsen, Ph.D., VP of Research. Ms Evren and Dr. Slichenmyer are the most recent additions to Merrimack's team, both arriving this summer. Dr. Khan joined in April 2006 while Mr. Mulroy and Dr. Nielsen, one of Merrimack's founders, have been involved with the Company since its inception.
"Bill brings to Merrimack deep experience across the entire drug development process as well as the management experience to help guide our organizational growth and strategic development," said Robert Mulroy, President & CEO. "Bill's skill set, coupled with the expertise of our existing team, will enable us to continue progressing on our journey toward making Merrimack a leading biopharmaceutical company."
Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid arthritis or with autoimmune uveitis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.
Source: Merrimack Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.